Taltz® ▼ (ixekizumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Taltz Summary of Product Characteristics (SmPC)

Taltz® ▼ (ixekizumab): Can Ixekizumab be used in Patients with COVID-19 (Coronavirus disease 2019)?

At this time, Lilly has not studied the use of ixekizumab in patients with COVID-19 nor in patients at risk of contracting COVID-19.

Ixekizumab Treatment in Patients with Suspected or Confirmed COVID-19

At this time, Lilly has not studied the use of ixekizumab in patients with coronavirus disease 2019 (COVID-19).

Ixekizumab should not be used during active COVID-19 infection and may be resumed after medical consultation and infection is resolved.1

  • If COVID-19 is confirmed, ixekizumab should be immediately discontinued and may be resumed after medical consultation and infection is resolved.1

  • If COVID-19 infection is suspected and signs and symptoms of acute infection occur, the patient should consult with their healthcare provider and seek medical advice for guidance on continuing and initiating ixekizumab treatment.1

Use of Ixekizumab in High Risk Areas

At this time, Lilly has not studied the use of ixekizumab in patients at risk of contracting COVID-19.

The decision on treatment remains at the discretion of prescribing physician.

COVID-19

COVID-19 is an active respiratory infection, which is typically mild and may also lead to acute respiratory distress syndrome which can be lethal.1

Infectious Disease Resources

For the most current information regarding COVID-19 and Coronavirus, please refer to the websites of local health authorities and/or WHO at WHO Coronavirus disease (COVID-19) outbreak.

Ixekizumab Infection-Related Warnings and Precautions according to the SmPC

Ixekizumab is contraindicated in patients with clinically important active infections (e. g. active tuberculosis).2

Treatment with ixekizumab is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections.2

Ixekizumab should be used with caution in patients with clinically important chronic infection or a history of recurrent infection. Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. If an infection develops, monitor carefully and discontinue ixekizumab if the patient is not responding to standard therapy or the infection becomes serious. Ixekizumab should not be resumed until the infection resolves.2

For further information please refer to the Taltz SmPC.

Therapeutic Indications

Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.2

Ixekizumab, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.2

Ixekizumab is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.2

Ixekizumab is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).2

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

Lilly = Eli Lilly and Company

WHO = World Health Organization

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: February 25, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question